MedPath
EMA Product

Awiqli

Product approved by European Medicines Agency (EU)

Basic Information

Awiqli

Regulatory Information

EMEA/H/C/005978

Authorised

May 17, 2024

March 21, 2024

1

March 5, 2025

Company Information

Denmark

Novo Alle Bagsværd - 2880

Novo Nordisk A/S

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of diabetes mellitus in adults

Overview Summary

Awiqli is a medicine used to treat adults with diabetes. It contains the active substance insulin icodec, a long-acting insulin.

© Copyright 2025. All Rights Reserved by MedPath